Stempoint Capital LP Makes New $4.19 Million Investment in Sensei Biotherapeutics, Inc. $FTH

Stempoint Capital LP bought a new position in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 132,873 shares of the company’s stock, valued at approximately $4,188,000. Stempoint Capital LP owned about 0.10% of Sensei Biotherapeutics at the end of the most recent quarter.

Separately, Renaissance Technologies LLC grew its holdings in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the last quarter. 10.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on FTH. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 target price on the stock. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 target price on the stock. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Finally, Oppenheimer began coverage on Sensei Biotherapeutics in a research note on Tuesday. They issued an “outperform” rating and a $60.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.75.

Sensei Biotherapeutics Trading Down 0.7%

Shares of FTH stock opened at $28.93 on Thursday. The stock has a market cap of $38.77 million, a PE ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 12 month low of $6.87 and a 12 month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. Equities analysts predict that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider directly owned 130,142 shares of the company’s stock, valued at $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the transaction, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 49,494 shares of company stock worth $1,188,822 in the last ninety days. Company insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.